Chemical: Drug
diltiazem

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.



PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for diltiazem

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No Clinical Annotations available VA
rs11191548 NC_000010.10:g.104846178T>C, NC_000010.11:g.103086421T>C, NG_042272.1:g.111886A>G, rs56425857, rs56937167
T > C
SNP
No VIP available CA VA
rs12946454 NC_000017.10:g.43208121A>T, NC_000017.11:g.45130754A>T, NM_001135704.1:c.-2315A>T, NM_133373.4:c.163+1494T>A, XM_005257673.1:c.-2311A>T, XM_005257674.1:c.-2314A>T, XM_005257675.1:c.-2315A>T, XM_005257676.1:c.-2468A>T, XM_005257677.1:c.-2314A>T, XM_005257678.1:c.-2311A>T, XM_005257679.1:c.-2311A>T, XM_005257680.1:c.-2468A>T, XM_005257681.1:c.-2311A>T, XM_005257682.1:c.-2311A>T, XM_005257683.1:c.-2311A>T, XM_005257684.1:c.-2311A>T, XM_011524253.1:c.163+1494T>A, XM_011525256.1:c.-2485A>T
A > T
SNP
No VIP available No Clinical Annotations available VA
rs1378942 NC_000015.10:g.74785026C>A, NC_000015.9:g.75077367C>A, NM_001127190.1:c.-66+2306C>A, NM_004383.2:c.-66+2306C>A, XM_005254165.1:c.-66+503C>A, XM_005254165.3:c.-66+503C>A, rs60607055
C > A
SNP
No VIP available No Clinical Annotations available VA
rs1530440 NC_000010.10:g.63524591C>T, NC_000010.11:g.61764833C>T, NM_173554.2:c.553-1106C>T, XM_005269598.1:c.679-1106C>T, XM_005269598.2:c.679-1106C>T, XM_005269599.1:c.679-1106C>T, XM_005269599.3:c.679-1106C>T, XM_005269600.1:c.553-1106C>T, XM_005269600.3:c.553-1106C>T, XM_005269601.1:c.538-1106C>T, XM_006717690.2:c.817-1106C>T, rs17282910, rs56596595
C > T
SNP
No VIP available No Clinical Annotations available VA
rs16948048 NC_000017.10:g.47440466A>G, NC_000017.11:g.49363104A>G, NM_001145365.1:c.-1454T>C, NM_014897.2:c.-950T>C, NR_110882.1:n.136+587A>G, NR_110883.1:n.31-1175A>G, NR_110884.1:n.58-1175A>G, rs58731904, rs61097478
A > G
SNP
No VIP available No Clinical Annotations available VA
rs16998073 NC_000004.11:g.81184341A>T, NC_000004.12:g.80263187A>T, NG_029501.1:g.1600A>T
A > T
SNP
No VIP available No Clinical Annotations available VA
rs17367504 NC_000001.10:g.11862778A>G, NC_000001.11:g.11802721A>G, NG_008766.1:g.1572A>G, NG_013351.1:g.8383T>C, NM_005957.4:c.236+160T>C, XM_005263458.1:c.359+160T>C, XM_005263458.2:c.359+160T>C, XM_005263459.1:c.305+160T>C, XM_005263460.1:c.236+160T>C, XM_005263460.3:c.236+160T>C, XM_005263461.1:c.236+160T>C, XM_005263461.3:c.236+160T>C, XM_005263462.1:c.236+160T>C, XM_005263462.3:c.236+160T>C, XM_005263463.1:c.-28+160T>C, XM_005263463.2:c.-28+160T>C, XM_011541495.1:c.356+160T>C, XM_011541496.1:c.359+160T>C, rs61351229
A > G
SNP
No VIP available No Clinical Annotations available VA
rs1801252 NC_000010.10:g.115804036A>G, NC_000010.11:g.114044277A>G, NG_012187.1:g.5231A>G, NM_000684.2:c.145A>G, NP_000675.1:p.Ser49Gly, rs12720482, rs3740152
A > G
SNP
S49G
No VIP available No Clinical Annotations available VA
rs1801253 NC_000010.10:g.115805056G>C, NC_000010.11:g.114045297G>C, NG_012187.1:g.6251G>C, NM_000684.2:c.1165G>C, NP_000675.1:p.Gly389Arg, rs12718339, rs17091259, rs28365052, rs59130083
G > C
SNP
G389R
No VIP available No Clinical Annotations available VA
rs3184504 NC_000012.11:g.111884608T>C, NC_000012.12:g.111446804T>C, NG_021216.1:g.45857T>C, NM_001291424.1:c.178T>C, NM_005475.2:c.784T>C, NP_001278353.1:p.Trp60Arg, NP_005466.1:p.Trp262Arg, XM_005253818.1:c.904T>C, XM_005253818.3:c.904T>C, XM_005253819.1:c.784T>C, XM_005253819.3:c.784T>C, XM_005253820.1:c.178T>C, XM_006719180.2:c.-18T>C, XM_011537719.1:c.904T>C, XM_011537720.1:c.904T>C, XM_011537721.1:c.178T>C, XM_011537722.1:c.1014T>C, XP_005253875.1:p.Trp302Arg, XP_005253876.1:p.Trp262Arg, XP_005253877.1:p.Trp60Arg, XP_011536021.1:p.Trp302Arg, XP_011536022.1:p.Trp302Arg, XP_011536023.1:p.Trp60Arg, XP_011536024.1:p.Gly338=, rs17519753, rs52803061, rs60790578
T > C
SNP
W60R
No VIP available No Clinical Annotations available VA
rs4149601 NC_000018.10:g.58149559G>A, NC_000018.9:g.55816791G>A, NG_029954.1:g.110182G>A, NM_001144964.1:c.-315-16229G>A, NM_001144965.1:c.-326G>A, NM_001144967.2:c.49-16229G>A, NM_001144968.1:c.24G>A, NM_001144969.1:c.24G>A, NM_001144971.1:c.-404G>A, NM_001243960.1:c.49-16229G>A, NM_015277.5:c.49-16229G>A, NP_001138440.1:p.Gln8=, NP_001138441.1:p.Gln8=, XM_005266666.1:c.49-16229G>A, XM_005266668.1:c.-326G>A, XM_006722426.2:c.49-16229G>A, XM_006722428.2:c.49-16229G>A, XM_011525887.1:c.24G>A, XP_011524189.1:p.Gln8=, rs57531784
G > A
SNP
Q8Q
VIP No Clinical Annotations available No Variant Annotations available
rs776746 NC_000007.13:g.99270539C>T, NC_000007.14:g.99672916T>C, NG_007938.1:g.12083G=, NG_007938.1:g.12083G>A, NM_000777.4:c.219-237A>G, NM_000777.4:c.219-237G>A, NM_001190484.2:c.219-237A>G, NM_001190484.2:c.219-237G>A, NM_001291829.1:c.-253-1A>G, NM_001291829.1:c.-253-1G>A, NM_001291830.1:c.189-237A>G, NM_001291830.1:c.189-237G>A, NR_033807.2:n.717-1A>G, NR_033807.2:n.717-1G>A, NR_033808.1:n.689-1G>A, NR_033809.1:n.581-237G>A, NR_033810.1:n.689-1G>A, NR_033811.1:n.321-1G>A, NR_033812.1:n.321-1G>A, XM_005250169.1:c.189-237G>A, XM_005250170.1:c.-357-1G>A, XM_005250171.1:c.-253-1G>A, XM_005250172.1:c.-254G>A, XM_005250173.1:c.-331-237G>A, XM_005250198.1:c.806-4288C>T, XM_006715859.2:c.219-237A>G, XM_011515843.1:c.-254A>G, XM_011515844.1:c.-229-237A>G, XM_011515845.1:c.-463-1A>G, XM_011515846.1:c.-331-237A>G, XM_011515847.1:c.-571-1A>G, XR_927383.1:n.344-237A>G, XR_927402.1:n.1466+48736T>C, rs10361242, rs11266830, rs386613022, rs58244770
C > T
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
  • d-cis-Diltiazem
Trade Names
  • Acalix
  • Adizem
  • Altiazem
  • Anginyl
  • Angizem
  • Anoheal
  • Apo-Diltiaz
  • Britiazim
  • Bruzem
  • Calcicard
  • Cardizem
  • Cardizem CD
  • Cardizem SR
  • Cardizen LA
  • Cartia XT
  • Citizem
  • Cormax
  • Deltazen
  • Dilacor
  • Dilacor-XR
  • Diladel
  • Dilcontin
  • Dilpral
  • Dilrene
  • Dilt-cd
  • Dilta-Hexal
  • Diltia
  • Dilticard
  • Dilzem
  • Dilzen
  • Endrydil
  • Herbesser
  • Incoril AP
  • Masdil
  • Novo-Diltazem
  • Nu-Diltiaz
  • Syn-Diltiazem
  • Tiamate
  • Tiazac
  • Tiazac Tildiem
  • Tiazac XC
  • Viazem
Brand Mixture Names

PharmGKB Accession Id

PA449334

Type(s):

Drug

Description

A benzothiazepine derivative with vasodilating action due to its antagonism of the actions of the calcium ion in membrane functions. It is also teratogenic.

Source: Drug Bank

Indication

For the treatment of Hypertension

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, diltiazem, like verapamil, inhibits the influx of extracellular calcium across both the myocardial and vascular smooth muscle cell membranes. The resultant inhibition of the contractile processes of the myocardial smooth muscle cells leads to dilation of the coronary and systemic arteries and improved oxygen delivery to the myocardial tissue.

Source: Drug Bank

Pharmacology

Diltiazem, a benzothiazepine calcium-channel blocker, is used alone or with an angiotensin-converting enzyme inhibitor, to treat hypertension, chronic stable angina pectoris, and Prinzmetal's variant angina. Diltiazem is a non-dihydropyridine (DHP)member of the calcium channel blocker class, along with Verapamil. Diltiazem is similar to other peripheral vasodilators. Diltiazem inhibits the influx of extra cellular calcium across the myocardial and vascular smooth muscle cell membranes possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum. The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.

Source: Drug Bank

Food Interaction

Take this medication 30 minutes before meals.|Avoid natural licorice.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Diltiazem is metabolized by and acts as an inhibitor of the CYP3A4 enzyme.

Source: Drug Bank

Protein Binding

70%-80%

Source: Drug Bank

Absorption

Diltiazem is well absorbed from the gastrointestinal tract but undergoes substantial hepatic first-pass effect.

Source: Drug Bank

Half-Life

3.0 - 4.5 hours

Source: Drug Bank

Toxicity

LD 50=740mg/kg (orally in mice)

Source: Drug Bank

Chemical Properties

Chemical Formula

C22H26N2O4S

Source: Drug Bank

Isomeric SMILES

CC(=O)O[C@@H]1[C@@H](Sc2ccccc2N(C1=O)CCN(C)C)c3ccc(cc3)OC

Source: OpenEye

Canonical SMILES

COC1=CC=C(C=C1)[C@@H]1SC2=CC=CC=C2N(CCN(C)C)C(=O)[C@@H]

Source: Drug Bank

Average Molecular Weight

414.518

Source: Drug Bank

Monoisotopic Molecular Weight

414.16132802

Source: Drug Bank

SMILES

COC1=CC=C(C=C1)[C@@H]1SC2=CC=CC=C2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O

Source: Drug Bank

InChI String

InChI=1S/C22H26N2O4S/c1-15(25)28-20-21(16-9-11-17(27-4)12-10-16)29-19-8-6-5-7-18(19)24(22(20)26)14-13-23(2)3/h5-12,20-21H,13-14H2,1-4H3/t20-,21+/m1/s1

Source: Drug Bank

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
CACNG1 (source: Drug Bank)

Drug Interactions

Interaction Description
amiodarone - diltiazem Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
amiodarone - diltiazem Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
amlodipine - diltiazem Diltiazem increases the effect and toxicity of amlodipine (source: Drug Bank)
amlodipine - diltiazem Diltiazem increases the effect and toxicity of amlodipine (source: Drug Bank)
aprepitant - diltiazem This CYP3A4 inhibitor increases the effect and toxicity of aprepitant (source: Drug Bank)
atazanavir - diltiazem Increases the effect and toxicity of diltiazem (source: Drug Bank)
atazanavir - diltiazem Increases the effect and toxicity of diltiazem (source: Drug Bank)
atenolol - diltiazem Increased risk of bradycardia (source: Drug Bank)
atenolol - diltiazem Increased risk of bradycardia (source: Drug Bank)
atorvastatin - diltiazem Diltiazem increases the effect and toxicity of atorvastatin (source: Drug Bank)
atorvastatin - diltiazem Diltiazem increases the effect and toxicity of atorvastatin (source: Drug Bank)
bromazepam - diltiazem Diltiazem may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or a reductin in the bromazepam dose. Monitor for changes in the therapeutic and adverse effects of bromazepam if diltiazem is initiated, discontinued or dose changed. (source: Drug Bank)
buspirone - diltiazem The calcium channel blocker increases the effect and toxicity of buspirone (source: Drug Bank)
buspirone - diltiazem The calcium channel blocker, diltiazem, increases the effect and toxicity of buspirone. (source: Drug Bank)
carbamazepine - diltiazem Diltiazem increases the effect of carbamazepine (source: Drug Bank)
carbamazepine - diltiazem Diltiazem increases the effect of carbamazepine (source: Drug Bank)
cerivastatin - diltiazem Diltiazem increases the effect and toxicity of the statin (source: Drug Bank)
cerivastatin - diltiazem Diltiazem increases the effect and toxicity of the statin (source: Drug Bank)
cilostazol - diltiazem Diltiazem increases the effect of cilostazol (source: Drug Bank)
cisapride - diltiazem Diltiazem increases the levels of cisapride (source: Drug Bank)
cisapride - diltiazem Diltiazem increases the levels of cisapride (source: Drug Bank)
cyclosporine - diltiazem Diltiazem increases the effect and toxicity of cyclosporine (source: Drug Bank)
cyclosporine - diltiazem Diltiazem increases the effect and toxicity of cyclosporine (source: Drug Bank)
diltiazem - amiodarone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
diltiazem - amiodarone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
diltiazem - amlodipine Increases the effect and toxicity of amlodipine (source: Drug Bank)
diltiazem - amlodipine Increases the effect and toxicity of amlodipine (source: Drug Bank)
diltiazem - aprepitant This CYP3A4 inhibitor increases the effect and toxicity of aprepitant (source: Drug Bank)
diltiazem - aprepitant This CYP3A4 inhibitor increases the effect and toxicity of aprepitant (source: Drug Bank)
diltiazem - atazanavir Atazanavir increases the effect and toxicity of diltiazem (source: Drug Bank)
diltiazem - atazanavir Atazanavir increases the effect and toxicity of diltiazem (source: Drug Bank)
diltiazem - atenolol Increased risk of bradycardia (source: Drug Bank)
diltiazem - atenolol Increased risk of bradycardia (source: Drug Bank)
diltiazem - atorvastatin Increases the effect and toxicity of atorvastatin (source: Drug Bank)
diltiazem - atorvastatin Increases the effect and toxicity of atorvastatin (source: Drug Bank)
diltiazem - buspirone The calcium channel blocker increases the effect and toxicity of buspirone (source: Drug Bank)
diltiazem - buspirone The calcium channel blocker, diltiazem, increases the effect and toxicity of buspirone. (source: Drug Bank)
diltiazem - carbamazepine Increases the effect of carbamazepine (source: Drug Bank)
diltiazem - carbamazepine Increases the effect of carbamazepine (source: Drug Bank)
diltiazem - cerivastatin Increases the effect and toxicity of the statin (source: Drug Bank)
diltiazem - cerivastatin Increases the effect and toxicity of the statin (source: Drug Bank)
diltiazem - cilostazol Increases the effect of cilostazol (source: Drug Bank)
diltiazem - cilostazol Increases the effect of cilostazol (source: Drug Bank)
diltiazem - cisapride Increases the levels of cisapride (source: Drug Bank)
diltiazem - cisapride Increases the levels of cisapride (source: Drug Bank)
diltiazem - cyclosporine Increases the effect and toxicity of cyclosporine (source: Drug Bank)
diltiazem - cyclosporine Increases the effect and toxicity of cyclosporine (source: Drug Bank)
diltiazem - lovastatin Increases the effect and toxicity of the statin (source: Drug Bank)
diltiazem - lovastatin Increases the effect and toxicity of the statin (source: Drug Bank)
diltiazem - mesoridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
diltiazem - mesoridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
diltiazem - metoprolol Increased risk of bradycardia (source: Drug Bank)
diltiazem - metoprolol Increased risk of bradycardia (source: Drug Bank)
diltiazem - midazolam The calcium channel blocker increases the effect and toxicity of the benzodiazepine (source: Drug Bank)
diltiazem - midazolam The calcium channel blocker increases the effect and toxicity of the benzodiazepine (source: Drug Bank)
diltiazem - moricizine Increased effect/toxicity of moricizine (source: Drug Bank)
diltiazem - moricizine Increased effect/toxicity of moricizine (source: Drug Bank)
diltiazem - pindolol Increased risk of bradycardia (source: Drug Bank)
diltiazem - pindolol Increased risk of bradycardia (source: Drug Bank)
diltiazem - propranolol Increased risk of bradycardia (source: Drug Bank)
diltiazem - propranolol Increased risk of bradycardia (source: Drug Bank)
diltiazem - quinidine Increases the effect and toxicity of quinidine (source: Drug Bank)
diltiazem - quinidine Increases the effect and toxicity of quinidine (source: Drug Bank)
diltiazem - quinidine Increases the effect and toxicity of quinidine (source: Drug Bank)
diltiazem - quinupristin This combination presents an increased risk of toxicity (source: Drug Bank)
diltiazem - quinupristin This combination presents an increased risk of toxicity (source: Drug Bank)
diltiazem - ranolazine Increased levels of ranolazine- risk of toxicity (source: Drug Bank)
diltiazem - ranolazine Increased levels of ranolazine- risk of toxicity (source: Drug Bank)
diltiazem - rifampin Rifampin decreases levels of diltiazem (source: Drug Bank)
diltiazem - rifampin Rifampin decreases levels of diltiazem (source: Drug Bank)
diltiazem - ritonavir Ritonavir increases diltiazem levels (source: Drug Bank)
diltiazem - ritonavir Ritonavir increases diltiazem levels (source: Drug Bank)
diltiazem - simvastatin Increases the effect and toicity of simvastatin (source: Drug Bank)
diltiazem - simvastatin Increases the effect and toicity of simvastatin (source: Drug Bank)
diltiazem - sirolimus Increases the effect and toxicity of sirolimus (source: Drug Bank)
diltiazem - sirolimus Increases the effect and toxicity of sirolimus (source: Drug Bank)
diltiazem - tacrolimus Increases levels of tacrolimus (source: Drug Bank)
diltiazem - tacrolimus Increases levels of tacrolimus (source: Drug Bank)
diltiazem - terfenadine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
diltiazem - terfenadine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
diltiazem - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
diltiazem - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
diltiazem - triazolam The calcium channel blocker increases the effect and toxicity of the benzodiazepine (source: Drug Bank)
diltiazem - triazolam The calcium channel blocker increases the effect and toxicity of the benzodiazepine (source: Drug Bank)
lovastatin - diltiazem Diltiazem increases the effect and toxicity of the statin (source: Drug Bank)
lovastatin - diltiazem Diltiazem increases the effect and toxicity of the statin (source: Drug Bank)
mesoridazine - diltiazem Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
mesoridazine - diltiazem Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
metoprolol - diltiazem Increased risk of bradycardia (source: Drug Bank)
metoprolol - diltiazem Increased risk of bradycardia (source: Drug Bank)
midazolam - diltiazem The calcium channel blocker increases the effect and toxicity of benzodiazepine (source: Drug Bank)
midazolam - diltiazem The calcium channel blocker increases the effect and toxicity of benzodiazepine (source: Drug Bank)
pindolol - diltiazem Increased risk of bradycardia (source: Drug Bank)
pindolol - diltiazem Increased risk of bradycardia (source: Drug Bank)
propranolol - diltiazem Increased risk of bradycardia (source: Drug Bank)
propranolol - diltiazem Increased risk of bradycardia (source: Drug Bank)
quinidine - diltiazem Diltiazem increases the effect and toxicity of quinidine (source: Drug Bank)
quinidine - diltiazem Diltiazem increases the effect and toxicity of quinidine (source: Drug Bank)
quinupristin - diltiazem This combination presents an increased risk of toxicity (source: Drug Bank)
ranolazine - diltiazem Increased levels of ranolazine - risk of toxicity (source: Drug Bank)
rifampin - diltiazem Rifampin decreases levels of diltiazem (source: Drug Bank)
rifampin - diltiazem Rifampin decreases levels of diltiazem (source: Drug Bank)
tamsulosin - diltiazem Diltiazem, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Diltiazem is initiated, discontinued, or dose changed. (source: Drug Bank)
tamsulosin - diltiazem Diltiazem, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Diltiazem is initiated, discontinued, or dose changed. (source: Drug Bank)
telithromycin - diltiazem Telithromycin may reduce clearance of Diltiazem. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Diltiazem if Telithromycin is initiated, discontinued or dose changed. (source: Drug Bank)
terfenadine - diltiazem Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
terfenadine - diltiazem Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thiopental - diltiazem The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Diltiazem, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Diltiazem if Thiopental is initiated, discontinued or dose changed. (source: Drug Bank)
thiopental - diltiazem The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Diltiazem, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Diltiazem if Thiopental is initiated, discontinued or dose changed. (source: Drug Bank)
thioridazine - diltiazem Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - diltiazem Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
timolol - diltiazem Additive effects of decreased heart rate and contractility may occur. Increased risk of heart block. (source: Drug Bank)
timolol - diltiazem Additive effects of decreased heart rate and contractility may occur. Increased risk of heart block. (source: Drug Bank)
tipranavir - diltiazem Tipranavir, co-administered with Ritonavir, may alter the concentration of Diltiazem. Monitor for efficacy and adverse/toxic effects of Diltiazem. (source: Drug Bank)
tolterodine - diltiazem Diltiazem may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity. (source: Drug Bank)
tolterodine - diltiazem Diltiazem may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity. (source: Drug Bank)
tramadol - diltiazem Diltiazem may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. (source: Drug Bank)
trazodone - diltiazem The CYP3A4 inhibitor, Diltizem, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Diltiazem is initiated, discontinued or dose changed. (source: Drug Bank)
trazodone - diltiazem The CYP3A4 inhibitor, Diltizem, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Diltiazem is initiated, discontinued or dose changed. (source: Drug Bank)
treprostinil - diltiazem Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. (source: Drug Bank)
triazolam - diltiazem The calcium channel blocker increases the effect and toxicity of the benzodiazepine (source: Drug Bank)
triazolam - diltiazem The calcium channel blocker increases the effect and toxicity of the benzodiazepine (source: Drug Bank)
voriconazole - diltiazem Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of diltiazem by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of diltiazem if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank)

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
Contraindicated With

Publications related to diltiazem: 13

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
T Cell-Mediated Hypersensitivity Reactions to Drugs. Annual review of medicine. 2014. Pavlos Rebecca, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Mechanisms and assessment of statin-related muscular adverse effects. British journal of clinical pharmacology. 2014. Moßhammer Dirk, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB summary: very important pharmacogene information for CYP3A5. Pharmacogenetics and genomics. 2012. Lamba Jatinder, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetic implications for eight common blood pressure-associated single-nucleotide polymorphisms. Journal of hypertension. 2012. Hamrefors Viktor, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A Common beta1-Adrenergic Receptor Polymorphism Predicts Favorable Response to Rate-Control Therapy in Atrial Fibrillation. Journal of the American College of Cardiology. 2012. Parvez Babar, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenetics and genomics. 2011. Hodges Laura M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A functional variant of the NEDD4L gene is associated with beneficial treatment response with beta-blockers and diuretics in hypertensive patients. Journal of hypertension. 2011. Svensson-Färbom Patrik, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective. The pharmacogenomics journal. 2010. Li J-L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Machine learning methods and docking for predicting human pregnane X receptor activation. Chemical research in toxicology. 2008. Khandelwal Akash, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica; the fate of foreign compounds in biological systems. 2008. Zhou S-F. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clinical pharmacology and therapeutics. 2006. Neuvonen Pertti J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacokinetics of diltiazem and its metabolites in relation to CYP2D6 genotype. Clinical pharmacology and therapeutics. 2002. Molden Espen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Med-psych drug-drug interactions update. Psychosomatics. 2002. Armstrong Scott C, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
54868-4970-0
DrugBank:
DB00343
ChEBI:
101278
KEGG Compound:
C06958
PubChem Compound:
39186
PubChem Substance:
180243
46505667
IUPHAR Ligand:
2298
2349
2512
2526
Drugs Product Database (DPD):
2244728
BindingDB:
50004704
ChemSpider:
35850
Therapeutic Targets Database:
DAP001262
FDA Drug Label at DailyMed:
61bf535a-3ed5-4c50-b285-6dcee0624c2d

Clinical Trials

These are trials that mention diltiazem and are related to either pharmacogenetics or pharmacogenomics.

No trials found.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.